Applied Dna Sciences INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
L1 Capital Global Opportunities Master Fund, Ltd. has filed an amendment to its Schedule 13G, reporting beneficial ownership of 539,892 shares of BNB PLUS CORP. common stock, representing 7.0% of the class.
L1 Capital Global Opportunities Master Fund, Ltd. has increased its beneficial ownership in BNB PLUS CORP. to 8.7%, acquiring 539,892 shares through warrant exercises.
Off the Chain LP and Off the Chain Capital, LLC have disclosed a 9.99% beneficial ownership stake in BNB Plus Corp., primarily through common stock and warrants.
Sabby Management, LLC and affiliated entities reported a 4.9% beneficial ownership stake in BNB Plus Corp. common stock as of December 31, 2025.
Anson Funds Management LP and its affiliates have filed an Amendment No. 3 to Schedule 13G, reporting a 4.9% beneficial ownership in Applied DNA Sciences, Inc. as of September 30, 2025.
S.H.N. Financial Investments Ltd. has amended its beneficial ownership in Applied DNA Sciences Inc., now holding 3.4% of the common stock through warrants.
Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Applied DNA Sciences, Inc. through a Schedule 13G filing.
Anson Funds Management LP and its affiliates have disclosed a beneficial ownership of 8.2% in Applied DNA Sciences Inc., totaling 573,538 shares.
Anson Funds Management LP and its affiliated entities have disclosed a beneficial ownership of 5.4% in Applied DNA Sciences Inc., totaling 3,142,032 shares of common stock.
Sabby Management, LLC, Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz have jointly disclosed a beneficial ownership of 5,224,206 shares, representing a 10.0% stake in Applied DNA Sciences Inc.'s common stock.